Notice: This company has been marked as potentially delisted and may not be actively trading. Obalon Therapeutics (OBLN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends OBLN vs. SRTS, ICAD, LUCD, MGRM, NSPR, GUTS, ICCM, CTSO, HSAQ, and NVNOShould you be buying Obalon Therapeutics stock or one of its competitors? The main competitors of Obalon Therapeutics include Sensus Healthcare (SRTS), iCAD (ICAD), Lucid Diagnostics (LUCD), Monogram Orthopaedics (MGRM), InspireMD (NSPR), Fractyl Health (GUTS), IceCure Medical (ICCM), Cytosorbents (CTSO), Health Sciences Acquisitions Co. 2 (HSAQ), and enVVeno Medical (NVNO). Obalon Therapeutics vs. Sensus Healthcare iCAD Lucid Diagnostics Monogram Orthopaedics InspireMD Fractyl Health IceCure Medical Cytosorbents Health Sciences Acquisitions Co. 2 enVVeno Medical Sensus Healthcare (NASDAQ:SRTS) and Obalon Therapeutics (NASDAQ:OBLN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking. Do institutionals & insiders have more ownership in SRTS or OBLN? 25.3% of Sensus Healthcare shares are held by institutional investors. Comparatively, 18.6% of Obalon Therapeutics shares are held by institutional investors. 9.4% of Sensus Healthcare shares are held by insiders. Comparatively, 8.1% of Obalon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts recommend SRTS or OBLN? Sensus Healthcare presently has a consensus price target of $14.67, suggesting a potential upside of 172.61%. Given Sensus Healthcare's stronger consensus rating and higher probable upside, equities analysts clearly believe Sensus Healthcare is more favorable than Obalon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sensus Healthcare 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Obalon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has higher earnings and valuation, SRTS or OBLN? Sensus Healthcare has higher revenue and earnings than Obalon Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSensus Healthcare$41.81M2.11$6.65M$0.4013.45Obalon Therapeutics$1.59M7.06-$12.33MN/AN/A Which has more risk & volatility, SRTS or OBLN? Sensus Healthcare has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Obalon Therapeutics has a beta of -1.23, meaning that its stock price is 223% less volatile than the S&P 500. Does the MarketBeat Community believe in SRTS or OBLN? Obalon Therapeutics received 62 more outperform votes than Sensus Healthcare when rated by MarketBeat users. However, 68.66% of users gave Sensus Healthcare an outperform vote while only 47.40% of users gave Obalon Therapeutics an outperform vote. CompanyUnderperformOutperformSensus HealthcareOutperform Votes18468.66% Underperform Votes8431.34% Obalon TherapeuticsOutperform Votes24647.40% Underperform Votes27352.60% Is SRTS or OBLN more profitable? Sensus Healthcare has a net margin of 15.90% compared to Obalon Therapeutics' net margin of -776.76%. Sensus Healthcare's return on equity of 12.60% beat Obalon Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sensus Healthcare15.90% 12.60% 11.38% Obalon Therapeutics -776.76%-161.38%-83.58% Does the media refer more to SRTS or OBLN? In the previous week, Sensus Healthcare had 1 more articles in the media than Obalon Therapeutics. MarketBeat recorded 1 mentions for Sensus Healthcare and 0 mentions for Obalon Therapeutics. Sensus Healthcare's average media sentiment score of 1.95 beat Obalon Therapeutics' score of 0.00 indicating that Sensus Healthcare is being referred to more favorably in the media. Company Overall Sentiment Sensus Healthcare Very Positive Obalon Therapeutics Neutral SummarySensus Healthcare beats Obalon Therapeutics on 16 of the 18 factors compared between the two stocks. Get Obalon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OBLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OBLN vs. The Competition Export to ExcelMetricObalon TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.23M$4.74B$5.84B$9.15BDividend YieldN/A39.90%4.75%3.85%P/E Ratio-0.8329.7626.4919.17Price / Sales7.0653.61435.3770.93Price / CashN/A51.1038.0134.83Price / Book1.876.577.644.62Net Income-$12.33M$90.91M$3.19B$246.06M Obalon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OBLNObalon TherapeuticsN/A$1.12-8.9%N/A+642.3%$11.23M$1.59M-0.832Analyst ForecastGap DownSRTSSensus Healthcare2.5511 of 5 stars$5.51+0.2%$14.67+166.2%+15.2%$90.31M$41.81M13.7840Positive NewsICADiCAD0.5804 of 5 stars$3.32-8.0%N/A+92.9%$88.11M$17.32M-25.54140Analyst UpgradeNews CoverageLUCDLucid Diagnostics3.1804 of 5 stars$1.46+7.4%$3.63+148.3%+13.2%$86.64M$4.19M-1.2870News CoverageGap UpHigh Trading VolumeMGRMMonogram Orthopaedics3.7969 of 5 stars$2.48-7.8%$4.00+61.3%-24.9%$85.09M$370,000.00-5.2828News CoverageNSPRInspireMD2.4218 of 5 stars$2.94+2.8%$4.75+61.6%+22.5%$76.68M$6.20M-3.9250Analyst ForecastGUTSFractyl Health2.1755 of 5 stars$1.58-4.8%$18.00+1,039.2%-82.7%$76.00M$120,000.00-0.13102ICCMIceCure Medical3.3265 of 5 stars$1.36-0.7%$2.70+98.5%+9.3%$75.48M$3.67M-4.6960CTSOCytosorbents2.5387 of 5 stars$1.30-0.8%$4.67+259.0%+15.0%$71.08M$36.35M-3.61220Analyst ForecastHigh Trading VolumeHSAQHealth Sciences Acquisitions Co. 2N/A$5.67+1.3%N/A-11.9%$63.57MN/A0.004NVNOenVVeno Medical1.4697 of 5 stars$3.56+2.0%N/A-29.1%$62.44MN/A-2.7619News CoverageHigh Trading Volume Related Companies and Tools Related Companies SRTS Competitors ICAD Competitors LUCD Competitors MGRM Competitors NSPR Competitors GUTS Competitors ICCM Competitors CTSO Competitors HSAQ Competitors NVNO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OBLN) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Obalon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Obalon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
